Cancer Research includes companies working on scientific research aimed at understanding the causes, prevention, diagnosis, treatment, and potential cures for cancer. It includes many disciplines, from biology and genetics, to clinical trials and drug development, with the ultimate goal of improving cancer care and outcomes. Cancer research companies are developing life-saving treatments and diagnostics for a growing market in high demand. These companies constantly innovate, have a global reach, and form important strategic partnerships, which makes them appealing to investors looking for profits and supporting health progress.
Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A
MorphoSys Declares Voluntary Delisting From Nasdaq
Inflation Drop Fuels Rate Cut Speculation, Investors Shift To Sector Laggards, Russell 2000 Surges Over 3.6%: This Week In The Markets
Consumer price index data this week provided encouraging signs that American inflation is moving ever closer to the Federal Reserve's much-discussed 2% target.This fueled speculation about interest
These Are the Stocks With the Highest Increase in Short Interest Within Life Sciences and Diagnostics - Baird
Merck's Acquisition of EyeBio Finalized
Merck (NYSE:MRK) is trending on Friday. The company announced the acquisition of EyeBio, introducing a novel candidate to Merk's pipeline, Restoret.What To Know: Restoret has shown promising results
Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $115
Morgan Stanley analyst Michael Ulz maintains Blueprint Medicines (NASDAQ:BPMC) with a Equal-Weight and raises the price target from $110 to $115.
Blueprint Medicines Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/12/2024 -2.53% Morgan Stanley $110 → $115 Maintains Equal-Weight 07/08/2024 5.95% Oppenheimer $114 → $1
What the 2000's Tech Bubble Says About Today's Suspected Rotation - Analyst
With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence - Goldman Sachs
Thursday, Pfizer Inc (NYSE:PFE) announced it selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist.Pfizer plans to
These Are the Weight Loss Drug Stocks With the Most Upside - SA Sentiment Survey
Novo's Ozempic Linked to Improved Brain Health: Study
Pfizer, L3Harris Technologies And More: CNBC's 'Final Trades'
Joshua Brown of Ritholtz Wealth Management named Pfizer Inc. (NYSE:PFE) as his final trade on the latest edition of CNBC's "Halftime Report Final Trades." On Thursday, Pfizer announced it will
Biogen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/12/2024 32.35% Piper Sandler $335 → $313 Maintains Overweight 06/28/2024 24.32% Needham $294 → $294
Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars
Friday, Immutep Limited (NASDAQ:IMMP) released results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase 2b trial of eftilagimod alfa (efti) in combination with Merck & Co Inc (NYSE:MRK) Keytruda (pembrolizumab) as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expression.
This Weight Loss Stock Is the Best Alternative to Eli Lilly, Novo - SA Sentiment
Eli Lilly, Novo Nordisk Shares Dip as Pfizer Ramps Up Diabetes Drug Competition
Shares of $Eli Lilly and Co(LLY.US)$ and $Novo-Nordisk A/S(NVO.US)$ finished lower on Thursday, perhaps influenced by competitive developments and regulatory updates in the pharmaceutical sector.
Gilead Sciences's Options Frenzy: What You Need to Know
Deep-pocketed investors have adopted a bearish approach towards Gilead Sciences (NASDAQ:GILD), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga
Beyond The Numbers: 6 Analysts Discuss Merck & Co Stock
During the last three months, 6 analysts shared their evaluations of Merck & Co (NYSE:MRK), revealing diverse outlooks from bullish to bearish.The table below summarizes their recent ratings,
The weight-loss drug market is too lucrative to be abandoned! After being hit, Pfizer has restarted.
Pfizer, a world-renowned pharmaceutical company, has decided to enter the lucrative weight loss drug market to improve its performance, which has been affected by the post-pandemic slump. Pfizer first evaluated the prospects of the weight loss drug market and estimated that the market will grow to around USD 130 billion in the next ten years, with oral tablets expected to account for about one-third of the market. As a result, Pfizer hopes to compete with Novo Nordisk and Eli Lilly and Co.'s popular injectable weight loss drugs by developing an oral weight loss drug called danuglipron. This oral weight loss drug does not require injections and is expected to rival traditional injectable drugs. However, Pfizer has been struggling to make progress in treating obesity.
Why Pfizer Stock Is Moving Higher on Thursday
Pfizer (NYSE:PFE) stock gained on Thursday after the company announced it will advance development of its once-daily Danuglipron.